Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.58 |
| ▸ | CDK2 | P24941 | 19/20 | 0.58 |
| ▸ | CDK1 | P06493 | 4/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.58 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.58 |
| ▸ | CCND1 | P24385 | 7/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500160 | 0.92 | CCNE1 (0.62) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL3937870 | 0.88 | MAPK1 (0.48) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL3939386 | 0.88 | CDK2 (0.46) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL4431545 | 0.86 | CCNE1 (0.43) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL4431054 | 0.85 | MAPK8 (0.42) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL4431115 | 0.85 | CDK2 (0.43) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL3945478 | 0.85 | CDK2 (0.43) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL3945490 | 0.84 | CDK2 (0.39) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL14092790 | 0.84 | CDK2 (0.41) | CCNE1CDK2CDK1CCNB1CCNE2 | |
| SCHEMBL4433010 | 0.83 | CDK2 (0.42) | CCNE1CDK2CDK1CCNB1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | claimed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| EP-3741375-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-11-25 | — | — | EP | disclosed |
| US-20200323900-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-10-15 | — | — | US | disclosed |
| US-20170209488-A1 | METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016207366-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-12-29 | — | — | WO | disclosed |
| WO-2009017454-A1 | NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017453-A1 | NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017455-A1 | A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | CCNE1 3534/4885CDK2 328/4885CDK1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.